Market Cap 217.09M
Revenue (ttm) 38.63M
Net Income (ttm) -41.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -106.29%
Debt to Equity Ratio 0.00
Volume 758,200
Avg Vol 965,802
Day's Range N/A - N/A
Shares Out 106.42M
Stochastic %K 43%
Beta 1.27
Analysts Strong Sell
Price Target $7.00

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications;...

Industry: Medical Devices
Sector: Healthcare
Phone: 301 944 1700
Address:
9713 Key West Avenue, Suite 400, Rockville, United States
PitchStack
PitchStack Jun. 6 at 9:36 PM
$MXCT We recently reviewed a new MaxCyte stock pitch from Substack. MaxCyte (NASDAQ: MXCT) 🇺🇸 | $ 228.58 M | Healthcare | Value MaxCyte, Inc. is a global life sciences company focused on next-generation cell therapies. The current valuation, with a market cap of $240 million and an enterprise value of $85 million, suggests significant upside potential. Furthermore, its robust core business benefits from high-margin consumable sales and strategic partnerships, such as with Vertex for the CASGEVY therapy. Additionally, MaxCyte's strong cash position and expanding SPL agreements offer attractive opportunities for future revenue growth. Link: https://doheenz.substack.com/p/maxcyte-mxct Our team also analysed 18 other pitches, with the full breakdown available at PitchStack: www.pitchstack-investing.com
0 · Reply
RocketThief
RocketThief Jun. 6 at 4:21 PM
$MXCT accumulating
0 · Reply
RocketThief
RocketThief Jun. 3 at 4:13 PM
$MXCT feels like a good swing spot
0 · Reply
jdlman
jdlman May. 27 at 7:51 PM
$MXCT nice day here
0 · Reply
Biotekman
Biotekman May. 13 at 12:18 AM
$MXCT Hi there! Not invested in MXCT, but in $IOVA. But this company is definitely in my watchlist! I found an interesting video. https://youtu.be/rO9g9ADgBEg?si=7uphg8VV3yULlcMK
1 · Reply
_www_larval_com_
_www_larval_com_ Apr. 15 at 6:03 PM
$MXCT has reversed -4% lower to 0% (~1Mv) a moment ago, 04/17 options, follow for more volatility.
0 · Reply
briefingcom
briefingcom Apr. 15 at 12:06 PM
Gapping down: $APLD -11.9% $ALGM -9.8% $FHTX -9.4% $MXCT -6.9% $KMTS -3%
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 8:58 AM
$MXCT Digging MaxCyte's cell engineering tech. Looks like they're crushing it with strategic platform licenses. Betting on their ExPERT platform to drive growth in cell therapy market. Watching closely for next moves. compelling writeup: https://beyondspx.com/article/maxcyte-mxct-pioneering-cell-engineering-excellence-for-the-next-generation-of-therapeutics
0 · Reply
Alberto1976
Alberto1976 Mar. 15 at 1:53 PM
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price $MXCT $SPX $SPY https://seekingalpha.com/article/4767856-maxcyte-strong-revenues-fast-growing-cell-therapy-market
0 · Reply
PenkeTrading
PenkeTrading Mar. 13 at 2:16 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of MaxCyte Inc. Is that bullish or bearish? $MXCT #MaxCyte #RsiOversold #NASDAQ
0 · Reply
Latest News on MXCT
MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript

May 10, 2025, 11:57 PM EDT - 6 weeks ago

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript


MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:52 PM EDT - 3 months ago

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript


MaxCyte Announces Retirement of Board Member Art Mandell

Dec 23, 2024, 2:00 AM EST - 6 months ago

MaxCyte Announces Retirement of Board Member Art Mandell


MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:01 PM EST - 8 months ago

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript


MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 31, 2024, 8:05 AM EDT - 8 months ago

MaxCyte to Participate in Two Upcoming Investor Conferences


MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 15, 2024, 8:05 AM EDT - 8 months ago

MaxCyte Appoints Cynthia Collins to its Board of Directors


MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Oct 10, 2024, 8:05 AM EDT - 9 months ago

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer


Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

Oct 4, 2024, 5:19 PM EDT - 9 months ago

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up


MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 12:09 AM EDT - 11 months ago

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript


MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

May 11, 2024, 8:35 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript


MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 10:40 PM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript


MaxCyte May Benefit From Potential Gene Therapy Approval

Nov 27, 2023, 8:00 AM EST - 1 year ago

MaxCyte May Benefit From Potential Gene Therapy Approval


MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 11:06 PM EST - 1 year ago

MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript


MaxCyte to Participate in Baird Global Healthcare Conference

Sep 5, 2023, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Baird Global Healthcare Conference


PitchStack
PitchStack Jun. 6 at 9:36 PM
$MXCT We recently reviewed a new MaxCyte stock pitch from Substack. MaxCyte (NASDAQ: MXCT) 🇺🇸 | $ 228.58 M | Healthcare | Value MaxCyte, Inc. is a global life sciences company focused on next-generation cell therapies. The current valuation, with a market cap of $240 million and an enterprise value of $85 million, suggests significant upside potential. Furthermore, its robust core business benefits from high-margin consumable sales and strategic partnerships, such as with Vertex for the CASGEVY therapy. Additionally, MaxCyte's strong cash position and expanding SPL agreements offer attractive opportunities for future revenue growth. Link: https://doheenz.substack.com/p/maxcyte-mxct Our team also analysed 18 other pitches, with the full breakdown available at PitchStack: www.pitchstack-investing.com
0 · Reply
RocketThief
RocketThief Jun. 6 at 4:21 PM
$MXCT accumulating
0 · Reply
RocketThief
RocketThief Jun. 3 at 4:13 PM
$MXCT feels like a good swing spot
0 · Reply
jdlman
jdlman May. 27 at 7:51 PM
$MXCT nice day here
0 · Reply
Biotekman
Biotekman May. 13 at 12:18 AM
$MXCT Hi there! Not invested in MXCT, but in $IOVA. But this company is definitely in my watchlist! I found an interesting video. https://youtu.be/rO9g9ADgBEg?si=7uphg8VV3yULlcMK
1 · Reply
_www_larval_com_
_www_larval_com_ Apr. 15 at 6:03 PM
$MXCT has reversed -4% lower to 0% (~1Mv) a moment ago, 04/17 options, follow for more volatility.
0 · Reply
briefingcom
briefingcom Apr. 15 at 12:06 PM
Gapping down: $APLD -11.9% $ALGM -9.8% $FHTX -9.4% $MXCT -6.9% $KMTS -3%
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 8:58 AM
$MXCT Digging MaxCyte's cell engineering tech. Looks like they're crushing it with strategic platform licenses. Betting on their ExPERT platform to drive growth in cell therapy market. Watching closely for next moves. compelling writeup: https://beyondspx.com/article/maxcyte-mxct-pioneering-cell-engineering-excellence-for-the-next-generation-of-therapeutics
0 · Reply
Alberto1976
Alberto1976 Mar. 15 at 1:53 PM
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price $MXCT $SPX $SPY https://seekingalpha.com/article/4767856-maxcyte-strong-revenues-fast-growing-cell-therapy-market
0 · Reply
PenkeTrading
PenkeTrading Mar. 13 at 2:16 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of MaxCyte Inc. Is that bullish or bearish? $MXCT #MaxCyte #RsiOversold #NASDAQ
0 · Reply
jParkz
jParkz Mar. 12 at 10:30 PM
News out $MXCT MXCT Price Target Alert: $6.00. Issued by BTIG https://marketwirenews.com/news-releases/mxct-price-target-alert-6-00-issued-by-btig-7047196044511166.html $MXCT
0 · Reply
briefingcom
briefingcom Mar. 12 at 12:20 PM
$MXCT: MaxCyte beats by 0.02; beats on revs https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250312045518MXCT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
JarvisFlow
JarvisFlow Mar. 12 at 12:00 PM
Stifel has adjusted their stance on MaxCyte ( $MXCT ), setting the rating to Buy with a target price of 11 → 9.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 11 at 8:17 PM
$MXCT MaxCyte sees FY25 core business revenue up 8%-15% The company said, "Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments. MaxCyte expects to end 2025 with $160 million in total cash, cash equivalents and investments."
0 · Reply
DonCorleone77
DonCorleone77 Mar. 11 at 8:16 PM
$MXCT MaxCyte reports Q4 EPS (10c), consensus (12c) Reports Q4 revenue $8.69M, consensus $7.91M. "We are pleased to report strong financial results in 2024, including a return to core revenue growth and disciplined cash management, driven by the execution of our team," said Maher Masoud, president and CEO of MaxCyte. "We signed a record six SPLs in 2024 and continue to see momentum in the SPL pipeline with the addition of TG Therapeutics early in 2025. We also implemented a more disciplined capital and operational approach at MaxCyte, which has already enabled new strategic initiatives, and a more efficient and streamlined business, underpinning our commitment to long-term value creation for our shareholders. In 2025, we will continue to drive strong commercial execution, support the progression of SPL programs through the clinic, and make disciplined investments to position MaxCyte as a premier cell engineering solutions provider, including the integration and growth of SeQure Dx."
0 · Reply
mikesterz7
mikesterz7 Mar. 11 at 8:14 PM
$MXCT Earnings Total revenue of $8.7 million in the fourth quarter of 2024, a decrease of 45% over the fourth quarter of 2023. The decrease in total revenue was due to multiple one-time approval milestones in the fourth quarter of 2023. Core business revenue of $8.6 million in the fourth quarter of 2024, an increase of 20% over the fourth quarter of 2023. Strategic Platform License (SPL) Program-related revenue was $0.1 million for the fourth quarter of 2024, compared to $8.5 million in the fourth quarter of 2023. Total revenue of $38.6 million for the full year 2024, a decrease of 6% over the full year 2023. Core business revenue of $32.5 million for the full year 2024, an increase of 9% over the full year 2023. SPL Program-related revenue was $6.1 million for the full year 2024, compared to $11.5 million in full year 2023. Total cash, cash equivalents and investments were $190.3 million as of December 31, 2024.
0 · Reply
KSY_B
KSY_B Jan. 28 at 6:32 PM
$MXCT breaking downtrend! Let's see next leg up!
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Jan. 15 at 2:30 PM
$MXCT Shows a potential move of +95%, forward charting up to 12 weeks; fore-chart imagines a bullish market, so I am betting on a bull market to continue. There's a chance to be driven down further around 4.20 area; the lower the buy in the better, of course. Technical indicators more than likely do not have enough time to reach break out level this week, but could starting 20Jan (day of inauguration).
1 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Jan. 15 at 5:39 AM
$MXCT IMHO, being held back artificially. I don't see a breakout this week but next week (Monday?) increases the possibility the more it is held back. Technical indicators are lined up, just needs volume. Price Target 02: $6.80 Price Target 03: $8.10
0 · Reply
BudCapital
BudCapital Jan. 14 at 1:01 PM
$LGVN $MXCT “MaxCyte reported preliminary core revenue for 2024 at the high end of the updated guidance range provided. The operating environment in the cell therapy industry is improving as we move into 2025; and we remain confident in the opportunity that exists for MaxCyte in the years ahead,” said Maher Masoud, President and CEO of MaxCyte. “In 2024, we increased the number of SPL customers by six, supported the commercial launch of the first non-viral gene edited cell therapy product approved by the FDA, and returned to healthy revenue growth while streamlining operations.”
0 · Reply
KCclean
KCclean Jan. 14 at 2:00 AM
$MXCT watching weekly close for new trend
1 · Reply
briefingcom
briefingcom Jan. 13 at 1:34 PM
$MXCT: MaxCyte sees Q4 revs above forecast https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250113062841MXCT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply